Gastrin-Releasing Peptide Receptor in Low Grade Prostate Cancer: Can It Be a Better Predictor Than Prostate-Specific Membrane Antigen?

• DOI: 10.3389/fonc.2021.650249
• Publication Date: 2021-03-29T06:14:13Z
• Authors: Pinuccia Faviana; Laura Boldrini; Paola Anna Erba; Iosè Di Stefano; Francesca Manassero; Riccardo Bartoletti; Luca Galli; Carlo Gentile; Massimo Bardi
• Keywords: Glutamate carboxypeptidase II; Prostate biopsy

The aim of the present study was to evaluate whether prostate cancer (PC) patients can be accurately classified on bases tissue expression gastrin-releasing peptide receptor (GRPR) and prostate-specific membrane antigen (PSMA). This retrospective included 28 with PC. Formalin-fixed paraffin-embedded samples were used for diagnosis. Immunohistochemistry staining techniques PSMA GRPR (both number cells expressed % area stained). To assess independent associations among selected variables, a multi-dimensional scaling (MDS) analysis used. It found that inversely correlated expression. Only expressing significantly related Gleason score. Both percentage close reaching significance at 0.05 level. MDS provided map overall, association confirming represent measures same dimension. In conclusion, our data showed should evaluated in biopsy specimens improve ability detect PC low grades earliest phases development. Considering GRPRs appear directly involved mechanisms tumor proliferation, advancements nuclear medicine radiotherapy focus this therapeutic approach Further studies laboratory will investigate molecular activation based GRPR.